Biocon Biologics secures US market entry date for Bmab 1200
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Sustainability is integral to Biocon's business purpose
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Five batches across four programs of Biocon Academy participated in the graduation ceremony
10+ emerging markets, Japan & ANZ transition in final phase
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Yesafili, received marketing authorization approval from the European Commission for the European Union
Total transaction value of the divestment is Rs. 3,660 million
Subscribe To Our Newsletter & Stay Updated